Prosecution Insights
Last updated: July 17, 2026
Application No. 18/559,861

MEDICAL DEVICE

Non-Final OA §102§103
Filed
Nov 09, 2023
Priority
Jun 04, 2021 — CN 202110625886.9 +1 more
Examiner
MCGINNITY, JAMES RYAN
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Shanghai Bluevascular Medtech Co. Ltd.
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
62 granted / 106 resolved
-11.5% vs TC avg
Strong +48% interview lift
Without
With
+47.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
24 currently pending
Career history
151
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
82.1%
+42.1% vs TC avg
§102
11.9%
-28.1% vs TC avg
§112
4.2%
-35.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 106 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Species I, claims 1-12 in the reply filed on March 26th, 2026, is acknowledged. Claim 13 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on March 26th, 2026. Claim Objections Claims 3 and 11 objected to because of the following informalities: in line 7 of claim 3, “exapand” should read “expand” to correct a spelling error; in lines 10-11 of claim 11, “shortest ones of the filter rods configured to be compressed in the sheath” should read “shortest ones of the filter rods are configured to be compressed in the sheath” to correct a grammatical error; in lines 11-12 of claim 11, “distal-to-heart ends of rest of the filter rods configured to be inserted into the limit sleeve” should read “distal-to-heart ends of the rest of the filter rods are configured to be inserted into the limit sleeve” to correct grammatical errors; in lines 12-13 of claim 11, “distal-to-heart ends of longest ones of the filter rods configued to be connected” should read “distal-to-heart ends of longest ones of the filter rods are configured to be connected” to correct grammatical and spelling errors. Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wilson et al. (Pub. No. 2004/0092989). Regarding claim 1, Wilson et al. teaches in the same field of endeavor of medical delivery devices (Abstract), and discloses a medical device (FIG. 1) comprising a delivery mechanism (50; FIGs. 5A-5B) and an implant (10), wherein the delivery mechanism comprises a delivery component (52, 54, and 56) and an assistive component (108; FIG. 16B; [0087]) that is connected to the delivery component ([0086-87] and FIG. 15B: 54 includes 92, which includes 104 and 106, which are attached to 108) and configured to be expanded or shrunk in a radial direction of the delivery component ([0089] 108 can be inflated, which FIGs. 15B and 16B illustrate causes radial expansion; [0111] 108 can also be deflated, illustrated by FIG. 17B), and the implant is detachably connected to the delivery component (FIG. 17B: when 108 is deflated, 10 remains in place); wherein the delivery mechanism is configured to deliver the implant to a predetermined position in a target lumen and release the implant ([0096] 10 is placed using 50), and the assistive component is radially expanded during the release of the implant so as to release the implant with a predetermined form in the predetermined position (FIGs. 15A-17B: 108 is expanded during deployment of 10 to place 10 in the deployed form). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-12 is/are rejected under 35 U.S.C. 103 as being unpatentable over McArthur et al. (U.S. Patent No. 10,722,338) in view of Wilson et al. Regarding claim 1, McArthur et al. discloses a medical device (FIGs. 1-7B), comprising a delivery mechanism (100) and an implant (170), wherein the delivery mechanism comprises a delivery component (FIG. 1: the body of 100), and the implant is detachably connected to the delivery component (FIGs. 3-5A: 170 is releasably attached to 100); wherein the delivery mechanism is configured to deliver the implant to a predetermined position in a target lumen and release the implant (C4:L41-44: a user may use 100 to place 170 is a desired location such as in the IVC). McArthur et al. does not disclose the delivery mechanism comprises an assistive component that is connected to the delivery component and configured to be expanded or shrunk in a radial direction of the delivery component, and the assistive component is radially expanded during the release of the implant so as to release the implant with a predetermined form in the predetermined position. Wilson et al. teaches in the same field of endeavor of medical delivery devices (Abstract), and discloses a medical device (FIG. 1) comprising a delivery mechanism (50; FIGs. 5A-5B) and an implant (10), wherein the delivery mechanism comprises a delivery component (52, 54, and 56) and an assistive component (108; FIG. 16B; [0087]) that is connected to the delivery component ([0086-87] and FIG. 15B: 54 includes 92, which includes 104 and 106, which are attached to 108) and configured to be expanded or shrunk in a radial direction of the delivery component ([0089] 108 can be inflated, which FIGs. 15B and 16B illustrate causes radial expansion; [0111] 108 can also be deflated, illustrated by FIG. 17B), and the implant is detachably connected to the delivery component (FIG. 17B: when 108 is deflated, 10 remains in place); wherein the delivery mechanism is configured to deliver the implant to a predetermined position in a target lumen and release the implant ([0096] 10 is placed using 50), and the assistive component is radially expanded during the release of the implant so as to release the implant with a predetermined form in the predetermined position (FIGs. 15A-17B: 108 is expanded during deployment of 10 to place 10 in the deployed form) for the purpose of securing the implant in place during delivery ([0087]). It would have been obvious to one of ordinary skill in the art before the effective filing date to have modified McArthur et al. to include an assistive component, as taught by Wilson et al., for the purpose of securing the implant in place during delivery. Regarding claim 2, McArthur et al. as modified by Wilson et al. further discloses the delivery component comprises a tube assembly (McArthur et al. 110 and 130) and a backward release component (McArthur et al. 133), the tube assembly comprising at least a first tube (McArthur et al. 130), the backward release component having a distal structure that is partially connected to the first tube and coaxially to the first tube (McArthur et al. FIG. 5A: 133 is connected to 130 is a coaxial manner), the assistive component sleeved over the first tube and proximal to the distal structure (Wilson et al. FIG. 17B: 108 is over the guidewire 60, which is the equivalent of 130 in McArthur et al., and 108 is proximal to the distal end), the implant detachably connected to the distal structure of the backward release component (McArthur et al. FIGs. 3-5A: 170 is releasably coupled to the distal end of 130). Regarding claim 3, McArthur et al. as modified by Wilson et al. further discloses the assistive component comprises a first transition section (Wilson et al. FIG. 16B: proximal end of 108), a main section (Wilson et al. FIG. 16B: body of 108), and a second transition section (Wilson et al. FIG. 16B: distal end of 108) which are axially connected successively (Wilson et al. FIG. 16B), and an outer diameter of the first transition section and an outer diameter of the second transition section decrease in directions away from the main section (Wilson et al. FIG. 16B: the proximal and distal ends of 108 decrease in their respective directions away from the body of 108); wherein the assistive component is configured to be at least partially movable in an axial direction of the first tube to radially expand the assistive component (Wilson et al. FIG. 16B: 108 expands away from 60). Regarding claim 4, McArthur et al. as modified by Wilson et al. further discloses an outer diameter of at least some segments of the main section is greater than or equal to a maximum outer diameter of the first transition section and the second transition section (Wilson et al. FIG. 16B: the body of 108 has a greater outer diameter than the proximal and distal ends). Regarding claim 5, McArthur et al. as modified by Wilson et al. further discloses the tube assembly further comprises a second tube (McArthur et al. 110) that is sleeved over the first body (McArthur et al. FIG. 3A: 110 is sleeved over 130) and axially movable relative to the first tube and the distal structure (McArthur et al. FIGs. 2-3: 110 is retracted and thereby axially movable relative to both 130 and 133); wherein the assistive component has a distal end that remains stationary relative to the first tube (Wilson et al. FIGs. 15B-17B: 108 remains stationary relative to 60), and a proximal end that is connected to a distal end of the second tube and movable synchronously with the second tube (Wilson et al. [0087] and FIG. 15B: the proximal end of 108 is connected to 130 by 110). Regarding claim 6, McArthur et al. as modified by Wilson et al. further discloses the delivery component further comprises a handle (McArthur et al. FIG. 1: the handle portion) provided with a first drive assembly (McArthur et al. 140) that is connected to a proximal end of the second tube (McArthur et al. C6:L42-57: 140 is connected to 110) and configured to drive the second tube to move axially relative to the first tube (McArthur et al. C6:L42-57: 140 is used to retract and deploy 110). Regarding claim 7, McArthur et al. as modified by Wilson et al. further discloses the first transition section and the second transition section are symmetrically disposed at two axial ends of the main section (Wilson et al. FIG. 16B: the proximal and distal ends of 108 are symmetric to each other). Regarding claim 8, McArthur et al. as modified by Wilson et al. further discloses the assistive component is a balloon (Wilson et al. [0087] 108 is a balloon) that is connected to and in communication with a perfusion channel defined in the first tube (Wilson et al. [0087] 108 is connected to a fluid passageway formed between 104 and 106) and the perfusion channel is configured to fill an agent into the balloon (Wilson et al. [0087] 108 is inflated by the fluid passageway; since “agent” is a broad term that just conveys an object which creates an effect, any fluid which causes the effect of inflating 108 can be considered an agent, and [0089] states that fluid is used to inflate 108). Regarding claim 9, McArthur et al. as modified by Wilson et al. further discloses the backward release component comprises a limit sleeve (McArthur et al. 135), a restraint member (McArthur et al. 131), and a connector (McArthur et al. 132), wherein the limit sleeve and the restraint member constitute the distal structure of the backward release component (McArthur et al. FIG. 3A: 131 and 135 are the distal end of 133), the limit sleeve is connected to and in communication with the first tube (McArthur et al. FIG. 3A: the distal end of 130 are connected to 135), the limit sleeve is axially stationary relative to the first tube (McArthur et al. FIG. 3A: 135 is secured to the end of 130, and is thereby stationary relative to 130); the restraint member is configured to be received in the limit sleeve (McArthur et al. FIG. 5A: 133 is received within 135); the connector is inserted into the first tube and movable relative to the first tube (McArthur et al. FIG. 3A: 132 goes within 130 and moves relative to 130), and a distal end of the connector is connected with the restraint member (McArthur et al. FIG. 3A: 132 is connected to 131); wherein the restraint member is engaged with the limit sleeve (McArthur et al. FIG. 3A: 131 is connected to 135) and the restraint member is detachably connected to the implant when the restraint member is at least partially located inside the limit sleeve (McArthur et al. FIG. 5A: 131 detaches from 170 when within 135), and the backward release component is disconnected from the implant when the restraint member is at least partially exposed from a distal end of the limit sleeve (McArthur et al. FIG. 5A: 170 disconnects from 100 when 131 is exposed from 135) and the restraint member is disengaged with the limit sleeve (McArthur et al. FIG. 5A: 131 does not contact 135), resulting from a movement of the first tube relative to the connector (McArthur et al. FIG. 5A: 130 moves relative to 135 when 131 disengages 170 from 100). Regarding claim 10, McArthur et al. as modified by Wilson et al. further discloses the delivery component further comprises a handle (McArthur et al. FIG. 1: the handle portion) provided with a second drive assembly (McArthur et al. 147; FIG. 6A), the handle connected to a proximal end of the connector (McArthur et al. FIGs. 6A-6A1: the handle portion is connected to the proximal end of 132), the second drive assembly connected to a proximal end of the first tube and configured to drive the first tube to move axially relative to the connector (McArthur et al. C12:L35-50: 147 is connected to 130 and used to move 130 relative to 132). Regarding claim 11, McArthur et al. as modified by Wilson et al. further discloses wherein a retrieval part (McArthur et al. 178; FIG. 5A) is configured to detachably connect to the backward release component (McArthur et al. FIG. 5A: 178 is releasably attached to 133). Regarding claim 12, McArthur et al. as modified by Wilson et al. further discloses the restraint member is a slider (McArthur et al. FIG. 5A: 131 slides according to the arrows) having a side wall defined therein with a groove (McArthur et al. 136); wherein the groove and an inner surface of the limit sleeve together limit a position of a proximal-to-heart end of the implant so as to connect the implant with the backward release component when the slider is at least partially received in the limit sleeve (McArthur et al. FIG. 5A: 135 and 136 limit the position of the proximal end of 170 while 131 is within 135), and the backward release component is disconnected from the implant when the slider moves axially relative to the limit sleeve to expose the groove from the limit sleeve (McArthur et al. FIGs. 3A and 5A: when 130 is moved proximally, 131 slides relative to 135 and 170 is disconnected from 100). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES RYAN MCGINNITY whose telephone number is (571)272-0573. The examiner can normally be reached M-Th 8 am-5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Elizabeth Houston can be reached at 571-272-7134. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES R MCGINNITY/Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Nov 09, 2023
Application Filed
Jun 26, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12672865
BACKSTOP LOADER
5y 3m to grant Granted Jul 07, 2026
Patent 12667362
EMBOLIC DEVICE DELIVERY SYSTEM
4y 5m to grant Granted Jun 30, 2026
Patent 12661104
SURGICAL PADS AND SPACERS
3y 8m to grant Granted Jun 23, 2026
Patent 12648768
LARGE PUSH-IN SUTURE ANCHOR
4y 10m to grant Granted Jun 09, 2026
Patent 12648784
MECHANICAL VENOUS CLOT RETRIEVAL
10m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+47.9%)
3y 4m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 106 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month